LLY

1,065.58

-1.06%↓

JNJ

222.68

+0.13%↑

ABBV

212.27

+0.31%↑

UNH

375.95

-0.6%↓

MRK

115.57

+0.93%↑

LLY

1,065.58

-1.06%↓

JNJ

222.68

+0.13%↑

ABBV

212.27

+0.31%↑

UNH

375.95

-0.6%↓

MRK

115.57

+0.93%↑

LLY

1,065.58

-1.06%↓

JNJ

222.68

+0.13%↑

ABBV

212.27

+0.31%↑

UNH

375.95

-0.6%↓

MRK

115.57

+0.93%↑

LLY

1,065.58

-1.06%↓

JNJ

222.68

+0.13%↑

ABBV

212.27

+0.31%↑

UNH

375.95

-0.6%↓

MRK

115.57

+0.93%↑

LLY

1,065.58

-1.06%↓

JNJ

222.68

+0.13%↑

ABBV

212.27

+0.31%↑

UNH

375.95

-0.6%↓

MRK

115.57

+0.93%↑

Accueil・Liste d'Actions・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Ouvert

28.22 -0.21

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

27.69

Max

29.03

Chiffres clés
By Trading Economics
Revenu	43M 13M
Ventes	29M 107M
BPA	0.25
Marge bénéficiaire	12.139
Employés	524
EBITDA	16M 8.2M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+125.44% upside

Dividendes
By Dow Jones
Prochains Résultats	6 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	17M 1.5B
Ouverture précédente	28.43
Clôture précédente	28.22

Immunocore Holdings PLC ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

1 juin 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1 juin 2026, 23:38 UTC

Acquisitions, Fusions, Rachats

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1 juin 2026, 23:37 UTC

Market Talk

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1 juin 2026, 23:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 juin 2026, 23:01 UTC

Market Talk

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1 juin 2026, 22:08 UTC

Acquisitions, Fusions, Rachats

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 juin 2026, 22:01 UTC

Acquisitions, Fusions, Rachats

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 juin 2026, 22:01 UTC

Acquisitions, Fusions, Rachats

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1 juin 2026, 21:55 UTC

Acquisitions, Fusions, Rachats

Greg Abel's Week Is Off to Quite a Start -- WSJ

1 juin 2026, 21:53 UTC

Market Talk

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1 juin 2026, 21:22 UTC

Market Talk

Acquisitions, Fusions, Rachats

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1 juin 2026, 20:50 UTC

Market Talk

Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

1 juin 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1 juin 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

1 juin 2026, 20:46 UTC

Acquisitions, Fusions, Rachats

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1 juin 2026, 20:22 UTC

Acquisitions, Fusions, Rachats

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1 juin 2026, 20:21 UTC

Acquisitions, Fusions, Rachats

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1 juin 2026, 20:21 UTC

Acquisitions, Fusions, Rachats

Array Digital Infrastructure Declares $11 Special Div

1 juin 2026, 20:20 UTC

Acquisitions, Fusions, Rachats

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1 juin 2026, 19:40 UTC

Market Talk

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1 juin 2026, 19:28 UTC

Market Talk

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1 juin 2026, 19:01 UTC

Market Talk

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1 juin 2026, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1 juin 2026, 18:54 UTC

Acquisitions, Fusions, Rachats

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1 juin 2026, 18:33 UTC

Market Talk

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1 juin 2026, 18:32 UTC

Market Talk

Precious Metals Fall to Start June -- Market Talk

1 juin 2026, 18:00 UTC

Acquisitions, Fusions, Rachats

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1 juin 2026, 17:18 UTC

Market Talk

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1 juin 2026, 17:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 juin 2026, 17:10 UTC

Market Talk

Acquisitions, Fusions, Rachats

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Comparaison

Variation de prix

Immunocore Holdings PLC ADR prévision

Objectif de Prix

By TipRanks

125.44% hausse

Prévisions sur 12 Mois

Moyen 65.13 USD 125.44%

Haut 100 USD

Bas 33 USD

Basé sur 9 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

9 ratings

Achat

Maintien

Vente

Basé sur 9 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.